bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.05.03.722506

NativeReady: an open benchmark and sequence-based triage model for native mass spectrometry suitability

Abstract

Native mass spectrometry is a central analytical method for characterizing intact proteins, antibody-drug conjugates, and non-covalent assemblies, and it is increasingly the deciding measurement in biotherapeutic development pipelines. A single screening attempt requires days of expression, purification, and buffer exchange into ammonium acetate, followed by 30 to 60 minutes of optimization on a Q-Exactive UHMR or comparable instrument. To our knowledge, no published sequence-based predictor currently estimates native MS suitability before experimental screening. We curated 634 unique proteins with documented native MS outcomes, drawn from a 232-protein hand-curated base set, 358 entries recovered from RCSB PDB by full-text searching for native MS terminology, and 44 evidence-based extractions from supplementary tables across 80 EuropePMC papers. We trained four model variants on this benchmark: a 36-feature BioPython physicochemical baseline, an ESM-2 linear probe, an ESM-2 PCA-256 random forest, and a combined model that concatenates ESM-2 PCA components with BioPython features. All variants were evaluated under cluster-aware 5-fold cross-validation (GroupKFold over ESM-2 embedding-similarity clusters) with isotonic calibration, and standard stratified 5-fold cross-validation is reported as a sensitivity analysis. Under cluster-aware 5-fold cross-validation (GroupKFold over ESM-2 embedding-similarity clusters, our defense against homology leakage), the combined model achieved an AUC of 0.869 plus or minus 0.036, robust against the original stratified-CV value (0.873) and the BioPython baseline (0.852). The ESM-2-only variants showed AUC drops of 0.024 to 0.046 between stratified and cluster-aware splits, indicating that some of the apparent ESM-2 contribution under standard CV reflects homology leakage. Negative recall was 9.4 percent under cluster-aware splitting versus 26.0 percent under stratified, confirming that the models apparent failure-detection capability was substantially inflated by within-fold homology. We report both numbers and treat the cluster-aware values as the primary results. We release the curated dataset, the trained model, and an interactive web tool at nativeready.netlify.app. In its current form, NativeReady should be interpreted primarily as a positive-suitability triage tool; failure prediction remains limited by the scarcity of experimentally documented negative cases. We propose a user-contribution mechanism to accumulate real failure data over time. To our knowledge, no published sequence-based predictor currently estimates native MS suitability before experimental screening, and NativeReady is the first open benchmark and triage model specifically designed for this task.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Znabu, B. F., Atif, Z.. 2026-05-06. NativeReady: an open benchmark and sequence-based triage model for native mass spectrometry suitability. https://doi.org/10.64898/2026.05.03.722506

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗